@Long_Life All I really know is what I read and it looks like that patent is not going to interfere with $MRNA development. If it turns out to be a problem MRNA will either pay them off or buy the company in its entirety. ABUS is worth only $425M (after recently doubling in price) while MRNA is worth $29B. Nothing is going to stop MRNA except an ineffective drug. That’s why I’m in MRNA and also trading in INO and NVAX, among others.
  • 1
@dennismccain @Long_Life I think $MRNA has to say they do not think their work is affected by the $ABUS patent. Any other kind of statement is exhibit A in the damages case. They would never have spent the likely $MILLION+ or so to challenge the patent validity if it didn’t affect their work. Period. The likelihood of a buyout or settlement on possibly hundreds of billions in revenue would be far more than simply to buy $ABUS for $1B. Which makes $ABUS an attractive investment right now. It will likely run up until exact settlement is released. Which could come Monday morning, as Phase 3 supposed to begin Monday. Otherwise injunction. Also coincidence they announce over a weekend that they receive gov money near the market cap of $ABUS?
  • 1
1 Like